<DOC>
	<DOCNO>NCT02073851</DOCNO>
	<brief_summary>Pilot study enrol 12 patient single investigational site Netherlands . Patients TAVR enrol receive Embolic Deflection Device throughout duration TAVR procedure .</brief_summary>
	<brief_title>DEFLECT II : A Study Evaluate Safety Performance TriGuard™HDH Patients Undergoing TAVR</brief_title>
	<detailed_description>Prospective , single center , single arm pilot study enrol 12 patient single investigational site netherlands . Patients meet eligibility criterion TAVR none exclusion criterion enrol receive Embolic Deflection Device throughout duration TAVR procedure .</detailed_description>
	<mesh_term>Aortic Valve Stenosis</mesh_term>
	<criteria>1 . The patient must ≥ 18 year age . 2 . The patient meet indication transcatheter aortic valve replacement procedure . 3 . The patient willing comply specify followup evaluation . 4 . The patient , legally authorize representative , informed nature study , agree provision provide write informed consent , approve appropriate Medical Ethics Committee ( EC ) . 1 . Patients undergoing transcatheter aortic valve replacement via transaxillary , subclavian , direct aortic route 2 . Pregnant nursing subject plan pregnancy period 1 year follow index procedure . Female subject childbearing potential must negative pregnancy test do within 7 day prior index procedure per site standard test . 3 . Patients know diagnosis acute myocardial infarction ( AMI ) within 72 hour precede index procedure ( accord definition ) AMI &gt; 72 hour precede index procedure creatine kinase creatine kinase fraction return normal limit time procedure . 4 . Patients currently experience clinical symptom consistent new onset AMI , nitrateunresponsive prolong chest pain . 5 . Patients impaired renal function ( estimate Glomerular Filtration Rate [ Estimated Glomerular Filtration Rate ] &lt; 30 , calculate serum creatinine CockcroftGault formula ) . 6 . Patients torturous/unsuitable anatomy related major cerebral artery aortic arch may interfere device deployment remain deployed . 7 . Patients platelet count &lt; 100.000 cells/mm³ &gt; 700.000 cells/mm³ white blood cell &lt; 3000 cells/mm³ within 7 day prior index procedure . 8 . Patients history bleed diathesis coagulopathy patient antiplatelet and/or anticoagulant therapy contraindicate , refuse transfusion . 9 . Patients receive organ transplant wait list organ transplant . 10 . Poor fluoroscopic visualization due obesity medical reason 11 . Hypotension require iv/ia medication therapy resuscitation defibrillation 12 . Patients know medical illness know history substance abuse may cause noncompliance protocol , confound data interpretation associate life expectancy le one year . 13 . Patients know hypersensitivity contraindication aspirin , heparin/bivalirudin , clopidogrel/ticlopidine , nitinol , stainless steel alloy , latex , and/or contrast sensitivity adequately premedicated . 14 . Patients history stroke transient ischemic attack ( TIA ) within prior 6 month . 15 . Patients active peptic ulcer upper gastrointestinal ( GI ) bleeding within prior 6 month . 16 . Patients present cardiogenic shock . 17 . Patients severe peripheral arterial disease precludes delivery sheath vascular access . 18 . Patients severe calcification/atheroma , friable mobile atherosclerotic plaque aortic arch 19 . Patients contraindication cerebral MRI . 20 . Patients go unprotected ( cerebral embolization ) cardiovascular procedure prior , post transcatheter aortic valve replacement procedure , postprocedure diffusionweighted magnetic resonance image evaluation 21 . Patients plan treatment investigational device procedure study period .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2015</verification_date>
	<keyword>TAVR</keyword>
</DOC>